APO Research
Talk to an analyst

APO RESEARCH · REPORT

Severe Acute Respiratory Syndrome (SARS) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Outlook and Growth Opportunities 2026

26 December 2025196 pages

Choose your research edition.

Industry ResearchSevere Acute Respiratory Syndrome (SARS) Therapeutics Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Severe Acute Respiratory Syndrome (SARS) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Severe Acute Respiratory Syndrome (SARS) Therapeutics market include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Severe Acute Respiratory Syndrome (SARS) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Severe Acute Respiratory Syndrome (SARS) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market.

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Company

CEL-SCI Corporation

GeneCure LLC

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Type

LCA-60

INO-4500

FDX-000

D-3252

CEL-1000

Others

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Application

Research Center

Hospital

Clinic

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Severe Acute Respiratory Syndrome (SARS) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Severe Acute Respiratory Syndrome (SARS) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Severe Acute Respiratory Syndrome (SARS) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Severe Acute Respiratory Syndrome (SARS) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Severe Acute Respiratory Syndrome (SARS) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Severe Acute Respiratory Syndrome (SARS) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Severe Acute Respiratory Syndrome (SARS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Acute Respiratory Syndrome (SARS) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Severe Acute Respiratory Syndrome (SARS) Therapeutics industry.

Chapter 3: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Severe Acute Respiratory Syndrome (SARS) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Severe Acute Respiratory Syndrome (SARS) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends Table 2. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers Table 3. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges Table 4. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints Table 5. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company, Product Type & Application Table 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of LCA-60 Table 15. Significant Companies of INO-4500 Table 16. Significant Companies of FDX-000 Table 17. Significant Companies of D-3252 Table 18. Significant Companies of CEL-1000 Table 19. Significant Companies of Others Table 20. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type (2021-2026) Table 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Research Center Table 26. Significant Companies of Hospital Table 27. Significant Companies of Clinic Table 28. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application (2021-2026) Table 32. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application (2027-2032) Table 33. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Region (2021-2026) Table 36. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Region (2027-2032) Table 38. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Market Share by Country (2021-2026) Table 41. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Market Share by Country (2027-2032) Table 43. CEL-SCI Corporation Company Information Table 44. CEL-SCI Corporation Business Overview Table 45. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 47. CEL-SCI Corporation Recent Development Table 48. GeneCure LLC Company Information Table 49. GeneCure LLC Business Overview Table 50. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 52. GeneCure LLC Recent Development Table 53. Humabs BioMed SA Company Information Table 54. Humabs BioMed SA Business Overview Table 55. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 57. Humabs BioMed SA Recent Development Table 58. Inovio Pharmaceuticals, Inc. Company Information Table 59. Inovio Pharmaceuticals, Inc. Business Overview Table 60. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 62. Inovio Pharmaceuticals, Inc. Recent Development Table 63. Nanotherapeutics, Inc. Company Information Table 64. Nanotherapeutics, Inc. Business Overview Table 65. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 67. Nanotherapeutics, Inc. Recent Development Table 68. Novavax, Inc. Company Information Table 69. Novavax, Inc. Business Overview Table 70. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 72. Novavax, Inc. Recent Development Table 73. Phelix Therapeutics, LLC Company Information Table 74. Phelix Therapeutics, LLC Business Overview Table 75. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 77. Phelix Therapeutics, LLC Recent Development Table 78. Protein Sciences Corporation Company Information Table 79. Protein Sciences Corporation Business Overview Table 80. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 82. Protein Sciences Corporation Recent Development Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Image Figure 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. LCA-60 Image Figure 8. INO-4500 Image Figure 9. FDX-000 Image Figure 10. D-3252 Image Figure 11. CEL-1000 Image Figure 12. Others Image Figure 13. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type (2021-2032) Figure 16. Research Center Image Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application (2021-2032) Figure 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • LCA-60
  • INO-4500
  • FDX-000
  • D-3252
  • CEL-1000
  • Others
Applications
  • Research Center
  • Hospital
  • Clinic
Companies covered
  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
  1. 2.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
  2. 2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers
  3. 2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints
3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Company
  1. 3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Product Type and Application
  6. 3.6 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Severe Acute Respiratory Syndrome (SARS) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type
  1. 4.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Type Introduction
  2. 4.1.1 LCA-60
  3. 4.1.2 INO-4500
  4. 4.1.3 FDX-000
  5. 4.1.4 D-3252
  6. 4.1.5 CEL-1000
  7. 4.1.6 Others
  8. 4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type
  9. 4.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Type (2021-2032)
  11. 4.2.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type (2021-2032)
5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Application
  1. 5.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Application Introduction
  2. 5.1.1 Research Center
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application
  6. 5.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application (2021-2032)
6 Severe Acute Respiratory Syndrome (SARS) Therapeutics Regional Value Analysis
  1. 6.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Severe Acute Respiratory Syndrome (SARS) Therapeutics Country-level Value Analysis
  1. 7.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CEL-SCI Corporation
  2. 8.1.1 CEL-SCI Corporation Company Information
  3. 8.1.2 CEL-SCI Corporation Business Overview
  4. 8.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  6. 8.1.5 CEL-SCI Corporation Recent Developments
  7. 8.2 GeneCure LLC
  8. 8.2.1 GeneCure LLC Company Information
  9. 8.2.2 GeneCure LLC Business Overview
  10. 8.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  12. 8.2.5 GeneCure LLC Recent Developments
  13. 8.3 Humabs BioMed SA
  14. 8.3.1 Humabs BioMed SA Company Information
  15. 8.3.2 Humabs BioMed SA Business Overview
  16. 8.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  18. 8.3.5 Humabs BioMed SA Recent Developments
  19. 8.4 Inovio Pharmaceuticals, Inc.
  20. 8.4.1 Inovio Pharmaceuticals, Inc. Company Information
  21. 8.4.2 Inovio Pharmaceuticals, Inc. Business Overview
  22. 8.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  24. 8.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
  25. 8.5 Nanotherapeutics, Inc.
  26. 8.5.1 Nanotherapeutics, Inc. Company Information
  27. 8.5.2 Nanotherapeutics, Inc. Business Overview
  28. 8.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  30. 8.5.5 Nanotherapeutics, Inc. Recent Developments
  31. 8.6 Novavax, Inc.
  32. 8.6.1 Novavax, Inc. Company Information
  33. 8.6.2 Novavax, Inc. Business Overview
  34. 8.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  36. 8.6.5 Novavax, Inc. Recent Developments
  37. 8.7 Phelix Therapeutics, LLC
  38. 8.7.1 Phelix Therapeutics, LLC Company Information
  39. 8.7.2 Phelix Therapeutics, LLC Business Overview
  40. 8.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  42. 8.7.5 Phelix Therapeutics, LLC Recent Developments
  43. 8.8 Protein Sciences Corporation
  44. 8.8.1 Protein Sciences Corporation Company Information
  45. 8.8.2 Protein Sciences Corporation Business Overview
  46. 8.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  48. 8.8.5 Protein Sciences Corporation Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst